AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 52 min read$ARCT

Arcturus Therapeutics Holdings Inc. (ARCT): Submission of Matters to a Vote of Security Holders

Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001768224 0001768224 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Jun 5, 2026, 9:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:46 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$ARCT
Neutral
high confidence
Mentioned
$ARCT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ARCTNeutralLow
01

Why it matters

Confirms governance outcomes: nine director nominees elected, say-on-pay approved on a non-binding basis, and Deloitte & Touche LLP ratified as independent auditor for the fiscal year ending Dec. 31, 2026.

02

Market read

Routine post-meeting governance disclosure; unlikely to drive material repricing absent other concurrent catalysts.

03

What to watch

Traders may watch for follow-on disclosures (e.g., subsequent proxy/board actions) rather than the vote tallies themselves.

Relevance 6/10Novelty 2/10Timing: Filed June 5, 2026 after the annual meeting vote results.

Background

The SEC 8-K summarizes matters submitted to a vote at Arcturus Therapeutics’ 2026 annual stockholders meeting on June 5, 2026.

Company-level read

Ticker impact

$ARCTNeutralHigh confidence
Context

Arcturus reported final results of its 2026 annual stockholder vote, including election of directors, say-on-pay approval, and Deloitte ratification.

Expected impact

Low near-term impact; any reaction is likely limited to governance/auditor optics rather than fundamentals.

Evidence & confidence

The filing discloses voting outcomes (director elections, non-binding compensation vote, and auditor ratification) without new clinical, regulatory, or financial datapoints.

Market effects

Sector

Minimal; governance mechanics are not sector-specific catalysts.

Regional

Minimal; US-listed biotech governance filing.

Global

Minimal; no cross-border deal/regulatory action described.

Counterpoint

What could challenge this read

If investors were concerned about auditor continuity or board turnover, the ratification/election results could reduce uncertainty, but the filing still lacks new fundamentals.

Key entities

  • issuer
    Arcturus Therapeutics Holdings Inc.

    NASDAQ-listed biotech that filed the 8-K with final stockholder vote results.

  • auditor
    Deloitte & Touche LLP

    Independent registered public accounting firm ratified for FY ending Dec. 31, 2026.

Read at source← All news

Related articles

AUG 7
$ARCTMed

Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership

Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.

allsci.com4 min
AUG 6
$ARCTMed

Arcturus Therapeutics Holdings Inc. (ARCT): Results of Operations and Financial Condition

Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrol

SEC EDGAR 8-K6 min
JUL 2
$ARCTMed

Arcturus Therapeutics Stock Rises 8% On Thermo Fisher Collaboration

Arcturus Therapeutics (ARCT) shares rose 7.84% to $7.43 on Nasdaq after the company said it entered a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis. Thermo Fisher will provide manufacturing, clinical research and commercialization support via its Accelerator platform, with exclusive commercial manufacturing rights if approved.

rttnews.com2 min
JUL 2
$TMOMed

Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy - Thermo Fisher Scientific (NYSE:TMO), Ar

Arcturus Therapeutics said it selected Thermo Fisher Scientific to support Phase 3 development of ARCT-032, an inhaled mRNA therapy for cystic fibrosis. Thermo Fisher will provide Phase 3 manufacturing and clinical research services, with Phase 3 expected to run via Thermo Fisher’s PPD if Phase 2 is positive. A separate deal could grant exclusive commercial manufacturing rights if ARCT-032 is approved. Arcturus shares were up 12.19% to $7.73.

benzinga.com3 min
JUL 2
$ARCTMed

Arcturus Therapeutics gains 5.8% on Thermo Fisher deal By Investing.com

Arcturus Therapeutics (NASDAQ:ARCT) rose 5.8% premarket after announcing a collaboration with Thermo Fisher Scientific (NYSE:TMO) for late-stage development and commercialization support of ARCT-032, an experimental mRNA cystic fibrosis treatment. Thermo Fisher will provide manufacturing and clinical research services; Arcturus expects to use Thermo Fisher’s clinical research business if mid-stage data are positive and grants exclusive commercial manufacturing rights if approved.

investing.com3 min